Patent application number | Description | Published |
20090118213 | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION - Oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with either overexpression of Apo-B100, expression of mutated Apo-B100 or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof. | 05-07-2009 |
20100210712 | Short RNA Antagonist Compounds for the Modulation of Target mRNA - The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells. | 08-19-2010 |
20100216864 | RNA Antagonist Compounds for the Modulation of PCSK9 - The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed. | 08-26-2010 |
20100227914 | RNA Antagonist Compounds for the Inhibition of Apo-B100 Expression - Short oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with Apo-B100 expression are provided. The oligonucleotides comprise deoxyribonucleosides and locked nucleic acids. | 09-09-2010 |
20110054011 | RNA Antagonist Compounds for the Modulation of FABP4/AP2 - Oligonucleotides directed against the FABP4 gene are developed for modulating the expression of FABP4 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding FABP4. Methods of using these compounds for modulation of FABP4 expression and for the treatment of diseases associated with over expression of FABP4 are provided. Examples of such diseases are the metabolic syndrome, diabetes, atherosclerosis, and inflammatory states such as arthritis. The oligomer may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid (LNA) or a combination thereof. | 03-03-2011 |
20110224280 | Pharmaceutical Composition Comprising Anti PCSK9 Oligomers - The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as HYPERCHOLESTEROLEMIA AND RELATED DISORDERS. | 09-15-2011 |
20120115936 | POTENT ANTI APOB ANTISENSE COMPOUNDS - The present invention relates to oligomer compounds (oligomers), which target APO-B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL cholesterol imbalance; dyslipidemias, e.g., familial combined dyslipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, statin-resistant hypercholesterolemia; coronary artery disease (CAD), coronary heart disease (CHD), atherosclerosis. | 05-10-2012 |
20120122954 | Antisense Oligomers Targeting PCSK9 - The present invention relates to oligomer compounds (oligomers), which target PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for the treatment of certain medical disorders, such as hypercholesterolemia and related disorders. | 05-17-2012 |
20120122955 | USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES - The present invention relates to the use of LNA antisense apoB oligonucleotides for the treatment of acute coronary syndrome. | 05-17-2012 |
20120322851 | ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES - The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer. | 12-20-2012 |